<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793648</url>
  </required_header>
  <id_info>
    <org_study_id>PI-0290-2012</org_study_id>
    <nct_id>NCT02793648</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ascorbic Acid and Tocopherol for Depression in Elderly.</brief_title>
  <official_title>Phase II, Double-blind, Randomized, 1-way Cross-over, to Investigate the Effectiveness of the Combination of Ascorbic Acid (Vitamin C) and Tocopherol (Vitamin E) Versus Placebo for the Treatment of Depressive Disorders in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yolanda de Diego Otero</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Mediterranean Institute for the Advance of Biotechnology and Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims to treat depression. The incidence of major depression in the elderly accounts&#xD;
      for between 3.6 and 4.8% and increases to 8 to 37.4% when depressive disorders in general is&#xD;
      studied. Besides depression in the elderly presents with cognitive impairment, impaired&#xD;
      physical and social functioning, and predisposes to suicide. These are patients who often&#xD;
      have multiple conditions and be taking numerous psychopharmacological treatments which&#xD;
      hinders further treatment. The clinical trial will analyze the improvement in&#xD;
      neuropsychiatric symptoms through different instruments The Beck Depression Inventory (BDI),&#xD;
      State-Trait Anxiety Inventory (STAI), Life Events (AV), World Health Organization Disability&#xD;
      Assessment Schedule 2.0 (WHODAS 2.0), Wechsler Memory Scale (WMS-III), Mini mental state&#xD;
      examination (MMSE), Clinical Global Impression (CGI) and metabolic changes in the blood test&#xD;
      measurements; after 12 weeks of antioxidant (Ascorbic acid and Tocopherol) treatment or&#xD;
      placebo, and then after 24 weeks on active treatment with the antioxidant combination&#xD;
      (Ascorbic acid and Tocopherol).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and&#xD;
      tocopherol, as therapy of the depressive disorder in the elderly.&#xD;
&#xD;
        -  Design: Pilot clinical trial, Phase II , 6-month randomized, double-blind&#xD;
           placebo-controlled one-way crossover clinical trial, with two treatment periods of 12&#xD;
           weeks duration.&#xD;
&#xD;
        -  Setting: Regional University Hospital, Malaga.&#xD;
&#xD;
        -  Subjects: people older tan 55 years diagnosed with depression.&#xD;
&#xD;
        -  Intervention: 50 participants randomly assigned, to receive antioxidant vitamins C&#xD;
           (ascorbic acid) and vitamin E (d-alpha-tocopherol) once a day or placebo for 12 weeks&#xD;
           double-blind. In Study Period 2, all participants receive (open) active treatment.&#xD;
           Outcome measures: improvement in depressive symptoms. Plasma antioxidant status, also&#xD;
           memory will be assessed by Wechsler Memory Scale (WMS-III), and cognitive improvement&#xD;
           will be analyzed using Mini mental state examination (MMSE) at 0, 3, 6 months during the&#xD;
           trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depressive symptoms through Beck Depression Inventory (BDI)</measure>
    <time_frame>0,3, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety through the State Anxiety Inventory (STAI-S)</measure>
    <time_frame>0, 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the memory through the Wechsler Memory Scale (WMS-III)</measure>
    <time_frame>0, 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive impairment through MINI MENTAL STATE EXAMINATION (MMSE)</measure>
    <time_frame>0,3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the disease through the Clinical Global Impression (CGI)</measure>
    <time_frame>0,3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the individual level of functioning through the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)</measure>
    <time_frame>0,3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the levels of blood oxidative stress through the antioxidant level</measure>
    <time_frame>0,3, 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability analyzing the registered side effects</measure>
    <time_frame>0,3, 6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>colloidal Silica 200mg twice a day for twelve weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha tocopherol</intervention_name>
    <description>Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Vitamin E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>colloidal silica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of mild or moderate depression by Mini International Neuropsychiatric&#xD;
             Interview (MINI).&#xD;
&#xD;
          -  Having more than 55 years old&#xD;
&#xD;
          -  Have signed the informed consent document before starting the participation in the&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any advanced severe or unstable disease.&#xD;
&#xD;
          -  Previous diagnose and / or presence of severe mental disorder.&#xD;
&#xD;
          -  Risk of suicidal behavior.&#xD;
&#xD;
          -  Any treatment regimen, including treatment with psychotropic drugs and / or&#xD;
             anticonvulsant therapy that has not been stable for a period â‰¥ 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Current treatment with more than two psychoactive medications, including medications&#xD;
             for seizures control.&#xD;
&#xD;
          -  Intake more than 100 mg of vitamin E or C a day in the last 4 months.&#xD;
&#xD;
          -  Hypoprothrombinemia secondary to vitamin K deficiency&#xD;
&#xD;
          -  Glucose 6-phosphate dehydrogenase deficiency (G-6-PD).&#xD;
&#xD;
          -  Treatment with oral anticoagulants.&#xD;
&#xD;
          -  Initiate or change the pharmacological or non-pharmacological interventions during the&#xD;
             course of the trial.&#xD;
&#xD;
          -  Allergy to the formula components (or excipient used)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia M Perez-Costillas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional universitario de Malaga. UGC Salud Mental.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric Service. Hospital Regional Universitario</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Mediterranean Institute for the Advance of Biotechnology and Health Research</investigator_affiliation>
    <investigator_full_name>Yolanda de Diego Otero</investigator_full_name>
    <investigator_title>MSc. PhD</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

